<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9445">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983981</url>
  </required_header>
  <id_info>
    <org_study_id>JB-01</org_study_id>
    <nct_id>NCT02983981</nct_id>
  </id_info>
  <brief_title>Topical Psoriasis Study for Patients Receiving Biologic Therapy</brief_title>
  <official_title>An Open-Label, Observational Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) BID in Psoriasis Patients Being Treated With Biologic Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psoriasis Treatment Center of Central New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Psoriasis Treatment Center of Central New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of
      Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who
      are receiving biologic therapy for at least 24 weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of
      Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who
      are receiving biologic therapy for at least 24 weeks.

      Adult male and female subjects with moderate to severe chronic plaque psoriasis All patients
      will receive Topicort® BID for 4 weeks.

      After week 4 patients will receive Topicort® BID on two consecutive days a week for 12
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis severity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Physician's Global Assessment x Body Surface Area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Severity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Physician's Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis severity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Body Surface area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dermatology life quality index</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topicort topical spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topicort Topical Spray</intervention_name>
    <description>open label Topicort spray</description>
    <arm_group_label>open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adults ≥ 18 years of age.

          2. Diagnosis of chronic plaque-type psoriasis.

          3. Able to give written informed consent prior to performance of any study related
             procedures.

          4. Treated with a biologic agent for a minimum of 24 weeks at baseline.

          5. Plaque-type psoriasis as defined at screening and baseline by BSA ≤ 5%.

          6. Females of childbearing potential (FCBP) must have a negative pregnancy test at
             Screening and Baseline. FCBP who engage in activity in which conception is possible
             must use one of the approved contraceptive options: hormonal contraception;
             intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female
             condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive
             sponge with spermicide.

          7. Subject must be in general good health (except for psoriasis) as judged by the
             Investigator, based on medical history, physical examination.

        Exclusion Criteria:

          1. &gt;5% Body Surface Area

          2. Any condition, which would place the subject at unacceptable risk if he/she were to
             participate in the study.

          3. Pregnant or breast feeding, or considering becoming pregnant during the study.

          4. Malignancy or history of malignancy, except for:

               1. treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;

               2. treated [ie, cured] malignancy with no evidence of recurrence within the
                  previous 5 years.

          5. Use of any investigational drug within 4 weeks prior to randomization, or within 5
             pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).

          6. Use of oral systemic medications for the treatment of psoriasis within 4 weeks
             (includes, but not limited to, oral corticosteroids, methotrexate, acitretin,
             apremilast and cyclosporine).

          7. Patient used other topical therapies to treat within 2 weeks of the Baseline Visit
             (includes, but not limited to, topical corticosteroids, vitamin D analogs, or
             retinoids).

          8. Patient received UVB phototherapy within 2 weeks of Baseline.

          9. Patient received PUVA phototherapy within 4 weeks of Baseline.

         10. Patient has a known hypersensitivity to the excipients of Topicort Spray® as stated
             in the label.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Bagel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>December 2, 2016</lastchanged_date>
  <firstreceived_date>October 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Desoximetasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
